TD Cowen Raises PTGX Price Target to $160
Key Points
- TD Cowen reiterated its Buy rating on Protagonist Therapeutics on October 21, 2026, while raising its price target to $160 from $155.
- TD Cowen's $160 price target implies 15.45% upside from Protagonist Therapeutics, Inc.'s ($PTGX) current $138.59 share price.
- The biotechnology firm recently traded around $138.59, sitting roughly 4.2% below its 50-day moving average and up 21.0% above its 200-day moving average.
- Wall Street maintains a strong buy consensus on the stock from 14 analyst opinions, with an average target price of $178.57.
Since the rating, $PTGX is up 1.3% to date (from the $138.08 close on Oct 21, 2026).
Get Protagonist Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $PTGX.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Protagonist Therapeutics, Inc. alert may contain errors. Disclosures
On October 21, 2026, TD Cowen maintained its Buy rating on Protagonist Therapeutics, Inc. PTGX and raised its price target on the stock from $155 to $160. The research note provides a forward-looking view from the firm, coming on the same day the company's shares closed at $138.08.
PTGX
Protagonist Therapeutics, Inc.
TD Cowen vs. the S&P 500
Hypothetical returns from TD Cowen's disclosed trades, not real profit or advice. How we model this.
TD Cowen's Call on Protagonist Therapeutics
In its research note published on October 21, 2026, TD Cowen kept a Buy rating in place while nudging its target higher by $5. Analysts hold a positive stance on the drug developer as it advances its pipeline of oral and injectable peptide treatments.
Other Institutional Activity in Protagonist Therapeutics
Farallon Capital Management LLC kept its holdings steady, ending with 6,348,906 shares worth about $889,735,682. RTW Investments LP grew its holdings by 2,024 shares, ending with 5,061,175 shares worth about $709,273,061. Johnson & Johnson kept its stake unchanged, holding 2,449,183 shares valued at about $343,228,504.
Protagonist Therapeutics, Inc. Stock Up 0.4%
The stock recently traded around $138.59 as of October 22, 2026, up about 0.4% from its event-day close of $138.08. Shares sit roughly 4.2% below their 50-day moving average of $144.72 and roughly 21.0% above their 200-day moving average of $114.53. The share price rests 13.8% below its 52-week high of $160.81 and 89.6% above its 52-week low of $73.08.
$PTGX price target
Protagonist Therapeutics, Inc. daily closes and this analyst's $160 target. Not advice.
Recent Earnings
Protagonist Therapeutics reported trailing-twelve-month revenue of $281,992,000 alongside basic earnings of $1.03 per share. The business posted a net profit margin of 29.4% and a return on equity of 11.0%. Market participants look ahead to the company's next financial results scheduled for release on November 5, 2026.
Insider Buying and Selling at Protagonist Therapeutics, Inc.
Director William D Waddill sold 9,000 shares at a price of $107.68 on June 10, 2026, for a total value of $969,120. The same director sold another 9,000 shares at $117.94 on June 23, 2026, totaling $1,061,460. Chief Executive Officer Dinesh V Patel sold 100,000 shares on August 11, 2026, valued at $14,890,799, and later sold 125,000 shares on September 10, 2026, worth $18,240,568.
Analysts Set New Price Targets
Citigroup maintained a Buy rating on August 31, 2026, raising its target from $175 to $182. Barclays maintained an Overweight rating on September 1, 2026, lifting its target from $153 to $180. BMO Capital maintained an Outperform rating on September 1, 2026, setting a target of $190 compared to $178 previously. UBS initiated coverage on October 12, 2026, with a Buy rating and a $184 price target. Overall, the stock carries a consensus recommendation of strong buy from 14 analyst opinions, with a mean price target of $178.57.
About Protagonist Therapeutics
Protagonist Therapeutics operates as a discovery and development biotechnology company based in Newark, California. The firm focuses on specialized peptide-based therapies, including an oral treatment for moderate-to-severe plaque psoriasis and an injectable treatment for the rare blood disorder polycythemia vera. These clinical programs drive institutional interest and ongoing analyst coverage.
Bottom Line
TD Cowen's updated price target reflects continued confidence in the drug developer's pipeline progress. Investors will monitor the upcoming earnings release on November 5, 2026, for further updates on clinical milestones and financial performance.
Related Filing Alerts
Source: TD Cowen's rating change on $PTGX (Oct 21, 2026). Written by software, not financial advice. How we make alerts